# Ravindran Kanesvaran

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/ravindran-kanesvaran/

## Facts

| Field | Value |
| --- | --- |
| Citations | 8,969 |
| Field | Renal cell carcinoma treatment |
| h-index | 44 |
| i10-index | 153 |
| Last Known Institution | SingHealth |
| OpenAlex ID | https://openalex.org/A5037495975 |
| ORCID iD | 0000-0002-2351-881X |
| Works | 435 |

## Researcher papers

- [Screening tools for multidimensional health problems warranting a geriatric assessment in older cancer patients: an update on SIOG recommendations](https://scholariq.org/papers/screening-tools-for-multidimensional-health-problems-warranting-a-geriatric/)
- [Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019](https://scholariq.org/papers/management-of-patients-with-advanced-prostate-cancer-report-of-the-advanced/)
- [The International Metastatic Renal Cell Carcinoma Database Consortium model as a prognostic tool in patients with metastatic renal cell carcinoma previously treated with first-line targeted therapy: a population-based study](https://scholariq.org/papers/the-international-metastatic-renal-cell-carcinoma-database-consortium-model-as-a/)
- [Renal cell carcinoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up](https://scholariq.org/papers/renal-cell-carcinoma-esmo-clinical-practice-guideline-for-diagnosis-treatment/)
- [Managing cancer patients during the COVID-19 pandemic: an ESMO multidisciplinary expert consensus](https://scholariq.org/papers/managing-cancer-patients-during-the-covid-19-pandemic-an-esmo-multidisciplinary/)
- [Evaluation of Clear Cell, Papillary, and Chromophobe Renal Cell Carcinoma Metastasis Sites and Association With Survival](https://scholariq.org/papers/evaluation-of-clear-cell-papillary-and-chromophobe-renal-cell-carcinoma/)
- [Analysis of Prognostic Factors of Comprehensive Geriatric Assessment and Development of a Clinical Scoring System in Elderly Asian Patients With Cancer](https://scholariq.org/papers/analysis-of-prognostic-factors-of-comprehensive-geriatric-assessment-and/)
- [Correction: Corrigendum: Patient-specific hepatocyte-like cells derived from induced pluripotent stem cells model pazopanib-mediated hepatotoxicity](https://scholariq.org/papers/correction-corrigendum-patient-specific-hepatocyte-like-cells-derived-from/)
- [Linguistic validation of the simplified Chinese version of the US National Cancer Institute’s patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE™)](https://scholariq.org/papers/linguistic-validation-of-the-simplified-chinese-version-of-the-us-national/)
- [Management of patients with advanced prostate cancer—metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022](https://scholariq.org/papers/management-of-patients-with-advanced-prostate-cancer-metastatic-and-or/)
- [EP12.01-31 Updated First-line Osimertinib in Asian patients with Advanced EGFR-mutated Lung Cancer](https://scholariq.org/papers/ep12-01-31-updated-first-line-osimertinib-in-asian-patients-with-advanced-egfr/)

## Researcher topics

- [Renal cell carcinoma treatment](https://scholariq.org/topics/renal-cell-carcinoma-treatment/)
- [Cancer Genomics and Diagnostics](https://scholariq.org/topics/cancer-genomics-and-diagnostics/)
- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Bladder and Urothelial Cancer Treatments](https://scholariq.org/topics/bladder-and-urothelial-cancer-treatments/)

## Researcher university

- [SingHealth](https://scholariq.org/institutions/singhealth/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.